Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina-Reference-Cited by-同舟云学术

Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina

Published:2024-06-03 Issue:4 Volume:8 Page:585-598
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Rojas-Roque Carlos^ORCID,Silvestrini Constanza^ORCID,Argento Fernando^ORCID,Sugg Daniela^ORCID,Augustovski Federico^ORCID,Coelli Jesica^ORCID,Espinola Natalia^ORCID

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s41669-024-00495-6.pdf

Reference40 articles.

1. World Health Organization (WHO). International Agency for Research on Cancer. International Agency for Research on Cancer. Incidence, mortality and prevalence by cancer site, 5-years prevalence (all ages). https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=32&key=asr&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1.

2. Institute for Health Metrics and Evaluation (IHME). Institute for Health Metrics and Evaluation (IHME). [cited 2021 Sep 13]. GBD Compare. https://vizhub.healthdata.org/gbd-compare/.

3. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53. https://doi.org/10.1016/S0140-6736(18)32552-2.

4. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;25(2):16061. https://doi.org/10.1038/nrdp.2016.61.

5. Chase DM, Wenzel L. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):421–31. https://doi.org/10.1586/erp.11.41.